OTCPicks.com

FEATURED COMPANY

NEXPLORE CORPORATION (OTC: NXPC)

Detailed Quote: www.otcpicks.com/quotes/NXPC.php

Company Profile: www.otcpicks.com/nexplore/nexplore.htm

NeXplore Technologies is developing a Web 2.0 search engine and an assortment of social networking portals and tools that will enable users to personalize their Web experience and tailor it to their unique needs, interests, and online pursuits. The Company’s social computing platform, MyCircle.com, offers an enhanced, user-friendly graphical interface search engine, combined with innovative backend technology, which enables users to improve the way they connect with information and other people on the Worldwide Web. MyCircle’s Web 2.0 interface provides users with an online tool for sharing their Blogs, Voice-Over IP, photos and documents, podcasts and videocasts, classified advertising, instant messages, SMS text messages, Chat and personal profiles.

NXPC News:

November 11 - Former Microsoft VP Rowland Hanson Joins NeXplore Advisory Board

Branding Mastermind Behind Microsoft Windows to Guide Business Development and Growth Strategy for NeXplore Search

NeXplore Corporation (OTC: NXPC) announced the appointment of Rowland Hanson to the NeXplore Corporation board of advisors.

Currently CEO of business strategy consulting firm The HMC Company, Mr. Hanson will draw upon his vast experience building brands and growing market share for some of the world's best known, high-growth companies to guide business development and growth initiatives for NeXplore Search (www.NeXplore.com), an innovative Web 2.0 search engine optimized for a superior end-user experience, rich-media display and social network integration.

Prior to founding The HMC Company, Mr. Hanson served as vice president of corporate communications for Microsoft, where he developed and executed the company's highly acclaimed branding strategy which included the market introduction of Microsoft's most popular product -- a graphical interface that Mr. Hanson named "Windows."

"What excites me about NeXplore Search is that the visually rich user interface engages consumers and, at the same time, reinvigorates an advertising medium that, although proven, is losing its luster as text overload leaves more and more consumers with search fatigue," said Hanson. "NeXplore Search is well-positioned to be at the forefront of the next generation of search, and I am pleased to be involved with NeXplore at such a pivotal moment. I look forward to helping the NeXplore executive team take this product and company to the next level."

"Rowland Hanson brings immense business experience, marketing insight and branding wisdom to NeXplore," said Edward Mandel, CEO of NeXplore Corporation. "His proven track record maps out perfectly with NeXplore's aggressive growth goals. Rowland's guidance will be instrumental as we move forward with strategic initiatives to accelerate popularity of NeXplore Search among consumers and drive traction of NeXplore Search among leading brand and direct-response advertisers. We are thrilled to have a professional of Rowland's caliber and distinction serving on the NeXplore advisory board."

Prior to Microsoft, Mr. Hanson served as vice president of worldwide marketing for Neutrogena Corporation, a skin care and cosmetics company that registered phenomenal growth through new product introductions and global partnering before being acquired by Johnson & Johnson.

Over the last several years, Mr. Hanson served as a consultant, CEO, president, and board of director member for several emerging companies.

Mr. Hanson served as president, CEO, and chairman of Amaze Inc., a multi-media software publisher of popular products such as The Far Side, Trivial Pursuit, Bloom County, and Berlitz theme computer calendars and screen savers. Hanson negotiated the sale of Amaze to Delrina Corporation.

Mr. Hanson was founder, CEO, and Chairman of iTravel Corporation, an exclusive developer of multi-media travel guides for United Airlines, United Vacations, and the travel agency network. Hanson negotiated the successful sale of iTravel to StarPress.

Mr. Hanson was business development consultant, branding consultant, and board member of ColdHeat, a company whose proprietary material science led to the successful introduction of several new consumer small appliances.

Mr. Hanson served as a business development consultant, branding consultant, and board member of The Nautilus Group, the developer and marketer of well-known fitness brands such as Bowflex, Nautilus, Schwinn Fitness, and StairMaster.

Mr. Hanson founded The b EQUAL Company with a mission to strengthen the child/parent bond by creating games that make learning a fun, interactive, family event. The b EQUAL Company partners included A&E (The History Channel / Biography), National Geographic, and DreamWorks, Discovery, among others. Hanson negotiated the merging of The b EQUAL Company into Specialty Board Games (SBG) of Toronto, Canada.

Mr. Hanson holds a BBA from Loyola University and an MBA from the Wharton School of Business (University of Pennsylvania).

FEATURED COMPANY

PERF GO GREEN HOLDINGS INCORPORATED (OTCBB: PGOG)

Detailed Quote: www.otcpicks.com/quotes/PGOG.php

Company Profile:
http://www.otcpicks.com/perf-go-green/perf-go-green.htm

Perf Go Green Holdings, Inc. is engaged in the creation and global marketing of 100% eco-friendly, non-toxic, food-contact-compliant, biodegradable plastic products. All Perf Go Green products are made from recycled plastics and completely break down in landfill within two years, leaving no toxic or visible residue, as compared to other plastics that take hundreds of years. Perf Go Green’s corporate name reflects its “Go Green” mission to develop, market and distribute biodegradable plastic products as a practical and viable solution to eliminating plastic waste from the world environment.

PGOG News:

November 11 - Perf Go Green Expands Business Development Team

Partners With GEM Business Development to Broaden Retail and Consumer Awareness and Accelerate Go-to-Market Approach

Perf Go Green Holdings, Inc. (OTCBB: PGOG) (“Perf Go Green”), a marketer and distributor of biodegradable plastics, announced the expansion of its business development team through a partnership with GEM Business Development. GEM will assist Perf Go Green in building brand equity with consumers, gaining additional retail distribution and leveraging its partnerships with strategic retailers.

The GEM team will be led by Rebecca Gournay, President, who has more than 15 years of consumer packaged goods experience in Sales Management & Marketing. Prior to co-founding GEM, she served as Franchise Business Director, Marketing & Sales Operations at Johnson & Johnson. While at Johnson & Johnson, she worked on leading brands such as Splenda®, Lactaid®, Band-Aid®, Tylenol® and Aveeno®.

“GEM's deep knowledge of the consumer packaged goods industry will be a great asset to Perf Go Green as we continue to grow,” said Chief Marketing Officer Linda Daniels. “We picked GEM to help us refine our go-to-market strategy in the retail marketplace, enabling shoppers to make better environmental choices when they purchase household products. Our expanded team of seasoned executives will deliver a comprehensive consumer marketing plan, refine our go-to-market structure, and support retailers in their sustainability efforts by focusing on our authentic brand to drive category sales.”

Founded in November 2007, Perf Go Green premiered at the March 2008 International Home and Housewares Show in Chicago, where its products were honored for their design quality and innovation. Perf Go Green is now shipping seven prominent biodegradable plastic products categories, including 13-gallon kitchen trash bags, 30- and 39-gallon lawn & leaf bags, plastic drop cloths, Doggie Duty Bags™ and cat pan liners. Its products are available nationwide at more than 12,000 retail outlets. They are also sold online through Amazon.com and drugstore.com.

FEATURED COMPANY

UNIVERSAL BIOENERGY INCORPORATED (OTC: UBRG)

Detailed Quote: www.otcpicks.com/quotes/UBRG.php

Company Profile: http://www.otcpicks.com/universal-bioenergy.htm

Universal Bioenergy, Inc. is a Mississippi-based company engaged in the production of renewable fuels through its subsidiary Universal Bioenergy North America, Inc. that operates a biodiesel refinery in Mississippi. The refinery intends to produce biodiesel fuel from various virgin vegetable oils, premium greases, and non-edible vegetable oil sources using their unique and economical process.

UBRG News:

November 10 - Universal Bioenergy, Inc. Negotiates for Process Technologies to Lower Biodiesel Production Costs

Universal Bioenergy, Inc. (OTC: UBRG) announced it is in negotiations for two process technologies that could lower costs for biodiesel production.

The first of these technologies will allow the use of lower cost, higher free fatty acid feedstocks while producing other value-added byproducts. These include a furnace oil and a lubricant base oil that can sell for prices 20-25% higher than biodiesel as stated by the technology developers. Another advantage is this process does not produce glycerol, which is quickly becoming more difficult to dispose of or sell.

The second process will allow the lowering of the reaction temperature by up to 35 degrees Fahrenheit while maintaining output. This chemically modified process can save energy and operating costs.

FEATURED COMPANY

RONN MOTOR COMPANY (OTC: RNNM)

Detailed Quote: http://www.otcpicks.com/quotes/RNNM.php

Company Profile: http://www.otcpicks.com/ronn-motor-company.htm

Headquartered in Austin, Texas, Ronn Motor Company, Inc. is a design and manufacturing company focused on the leading edge engineering of environmentally friendly, finely built premium automobiles and technology. These technology systems include Hydrogen Fuel, Fuel cells, and Plug in-electrics will be incorporated into our automobiles and made available for aftermarket applications. Our products, coupled with RMC's core values of a strong sense of ethics, environmental sensitivity and premium quality, position the company as one of the new leaders in an automotive industry transitioning toward fuel efficiency.

RNNM News:

November 11 - Ronn Motor Company: 'Speculative Buy' Rating, Target Price $0.84 by Beacon Equity Research

Ronn Motor Company (OTC: RNNM) has received a Speculative Buy rating with a price target of $0.84 by Beacon Analyst, Victor Sula, Ph.D.

The full report is available at www.beaconequity.com/main/Page-data/Adpages/RNNM.

In the report, the analyst writes, “The Company’s H2GOTM system offers an immediate solution to the transportation industry for greenhouse gases emissions reduction. With the long term high oil prices environment a reality, RNNM solution has the potential to rapidly gather market share and report double-to-triple digits growth in sales. … Over the long term, the Company plans to maintain a double-digit growth in revenue due to increased acceptance of its offering and rollout of Hydrogen/Electric Plug-in Hybrid in 2010.”

Comparable companies in the hydrogen or exotic car manufacturing segment include Ballard Power Systems Inc. (Nasdaq: BLDP), FuelCell Energy Inc. (Nasdaq: FCEL), Plug Power Inc. (Nasdaq: PLUG) and Ener1 Inc. (AMEX: HEV).

November 10 - Frigette's Projection of Three-Year Retail Sales of One Million Units of Ronn Motor Company's H2GO™ Real Time Hydrogen Injection System Reinforced After Strong SEMA Response

Ronn Motor Company, Inc. (OTC: RNNM) announced that after strong SEMA response, the Company is reinforcing Frigette's projection of three-year retail sales of Ronn Motor Company's proprietary H2GO(TM) Real-Time Hydrogen Injection system could be potentially one million units globally, producing retail revenues potentially of up to $1 Billion in retail sales globally within the three years.

Ronn Maxwell, CEO of Ronn Motor Company, said, "The H2GO(TM) Real-Time Hydrogen Injection system was recently unveiled by Tommy DuPont, Publisher of the world renowned 'DuPont Registry' and revealed to the world at SEMA, the world's largest and most recognized automotive aftermarket convention show. The H2GO(TM) system is the catalyst behind the world's First Eco-Exotic sports car named the 'SCORPION(TM).' The Scorpion(TM) and the H2GO(TM) system were one of the most talked about features at this year's show and received unprecedented media coverage for its one-of-a-kind Green technologies that increase fuel mileage between 15-35% on any internal combustion engine while reducing noxious emissions to nearly zero.

"We are currently finalizing Global Distribution and manufacturing contracts with Frigette which is the largest aftermarket automotive manufacturer and distributor in the U.S. with nine regional distribution centers and over 5,000 distributors. Frigette products are sold directly or indirectly to over 170,000 locations worldwide. Frigette has distribution presence in the U.S.A., Europe, China, India and Russia."

Ronn Motor Company projections are based on assumptions from Frigette directly. In a prior news release, Mr. Phillip Kreymer, Director of Marketing at Frigette, said sales of one million units over the next three years are easily within Frigette's manufacturing and distribution capabilities and with a suggested retail price of $999.00 that would possibly produce revenues in the one billion dollar range.

Frigette is supplying products to many Original Equipment vehicle manufacturers including General Motors, Ford, Honda, Isuzu, Jaguar, Mazda, Nissan, and Subaru, and has been awarded the coveted "Q1 Supplier Award" by Ford Motor Company and the "First Team Supplier Award" by Nissan Motors of America. We also supply products to thirty-nine (39) OEM Recreational Vehicle manufacturers.

Frigette quality control standards have been approved by Chrysler Motors, Ford Motor Company, General Motors, Honda, Hyundai, Isuzu, Jaguar, Mazda, Nissan, Saturn, Subaru, GAZ, VAZ, Volvo, Winnebago, and others. Frigette's distributor network and key installers number in excess of 500 and have installation capabilities to support the Frigette products to the new car dealers who do not wish to perform installations. This assures the O.E.M. manufacturer that quality products, which they have approved, can be installed on their vehicles even though the car dealer may not wish to make the installation.

FEATURED COMPANY

BRITE-STRIKE TECHNOLOGIES INCORPORATED (OTC: BSTI)

Detailed Quote: www.otcpicks.com/quotes/BSTI.php

Company Profile: http://www.otcpicks.com/brite-strike/brite-strike.htm

Brite-Strike Tactical Illumination Products, Inc. was started by two police officers to create world-class tactical LED flashlights that had the features that police officers and citizens need to keep them safe. Brite-Strike makes a promise to always use the latest technology, world-class components, highest design and manufacturing standards, so consumers can rely on Brite-Strike products when they are needed.

BSTI News:

November 6 - Brite-Strike Tactical Illumination Products, Inc.'s Personal Protection System to Be Featured in the Prestigious Frontgate Christmas Catalog

Brite-Strike Tactical Illumination Products, Inc. (OTC: BSTI) announced that its "Lightning Strike" Personal Protection System will be featured in Frontgate's national Christmas catalog, and that shipments for the initial order will begin this week. The product is also being carried at 28 BJ's Wholesale Club locations, which can be found at www.brite-strike.com.

"This product, for the money, may be the most effective defensive tool available for women today, particularly in preventing assaults and rapes," said Glenn Bushee, President of Brite-Strike. "The gift set includes a powerful, but compact, tactical flashlight, with the patented tactical touch hi-low-strobe switch, a leather holster, as well as a personal safety alarm, that can emit a shrieking noise of up to 125 db, and can be effective in warding off dogs and assailants. The package includes other accessories, and is packaged in a presentation gift box."

The company also announced that sales of its flagship model, the "Tactical Blue-Dot" flashlight, currently being featured in the Herrington Catalog, remain very strong, and are expected to significantly exceed last year's sales, even in this challenging economic environment. The company has been informed that its product is the top selling product in the catalog at that price-point. "In tough economic times, such as now, the number of robberies and assaults rise dramatically, which increases the demand for all our products," said Mr. Bushee, president of Brite-Strike.

In other news, the company announced that it had shipped its first order to the Pennsylvania Prison System, an area where the company see's significant growth opportunities. The company is also currently in discussions with one major national retailer for the placement of the "Lightning Strike," and is in late-stage testing with one branch of the US Military.

The company recently filed a Form 15 with the SEC. This form is in preparation for the company's financial audit, and intent to file as an SEC reporting company, with application to file for listing on the OTC BB the first half of 2009.

"We are extremely optimistic about the future of Brite-Strike. We feel the current share price dramatically undervalues the company, and its long-term growth prospects. We project dramatic increase in revenues over the next several years, both from our existing product line, as well as new products," said Mr. Bushee. "We appreciate our loyal shareholders, and in acknowledgement of their support, we would like to offer any shareholders ordering product through customer service, at 781-585-5509, a discount on all their purchases, with free gift-wrapping for all our customers for the holiday season."

STOCKS TO WATCH

OPTIMER PHARMACEUTICALS INCORPORATED (NASDAQ: OPTR)
"Up 78.92% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/OPTR.php

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. OPT-80 is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic being developed for the treatment of travelers’ diarrhea, a form of infectious diarrhea.

OPTR News:

November 10 - Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80

OPT-80 Achieves its Primary Endpoint of Clinical Cure with a Lower Recurrence Rate vs. Vancocin®

Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) released positive top-line results from a pivotal Phase 3 clinical study of the Company’s lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile Infection (CDI).

92.1% of patients treated with OPT-80 (per protocol population) achieved clinical cure vs. 89.8% for Vancocin. In addition, only 13.3% of patients treated with OPT-80 experienced a recurrence vs. 24.0% for Vancocin (p = 0.004). Patients treated with OPT-80 had a global cure (cure with no recurrence within four weeks) of 77.7%, which was greater than Vancocin at 67.1% (p = 0.006). OPT-80 was well-tolerated.

"We are very pleased with the results of this study, the first of our two pivotal Phase 3 trials. This study highlights the important differentiating features of OPT-80, including lower recurrence and higher global cure rate than Vancocin, the only FDA approved antibiotic for the treatment of CDI,” commented, Michael N. Chang, Optimer’s Chief Executive Officer. “I believe OPT-80 will be an important therapeutic option for CDI, an infection that currently has limited treatment options and affects more than 500,000 patients in the United States annually with growing incidence worldwide. Our next step is to complete the on-going second Phase 3 study at clinical sites in Europe and North America to support an NDA filing."

The OPT-80 clinical trial (Protocol 101.1.C.003) is the largest single comparative study ever conducted against Vancocin. The detailed data from the study will be presented at a medical conference in the near future.

The Per Protocol (Microbiologically Evaluable) Population is the patient group with CDI confirmed by diarrhea with a positive toxin assay, met all inclusion/exclusion criteria, and received at least 3 days of therapy and were considered a failure or at least 8 days of therapy and were considered a cure.

The Modified Intent-to-Treat Population is the patient group with CDI confirmed by diarrhea with a positive toxin assay and received at least one dose of study medication.

OPT-80 Clinical Study Design

In this multi-center, randomized, double-blind Phase 3 clinical trial, 629 adult subjects were enrolled. Subjects with confirmed CDI received either 200 mg OPT-80 dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of OPT-80 was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure, an exploratory endpoint, was defined as patients who were cured and did not have a recurrence.

ABOUT CLOSTRIDIUM DIFFICILE INFECTION

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. CDI typically develops from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, allowing C. difficile bacteria to flourish.

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Higher incidence and severity of CDI, increased treatment failures with standard therapies and the emergence of the hypervirulent BI (NAP1/027) strain of C. difficile have combined to result in greater awareness of CDI and growing concern among medical professionals and public health officials.

ABOUT OPT-80

OPT-80 is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of OPT-80 may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

LODGENET INTERACTIVE CORPORATION (NASDAQ: LNET)
"Up 15.38% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/LNET.php

LodgeNet Interactive Corporation is the leading provider of media and connectivity solutions designed to meet the unique needs of hospitality, healthcare and other guest-based businesses. LodgeNet Interactive serves more than 1.9 million hotel rooms representing 10,000 hotel properties worldwide in addition to healthcare facilities throughout the United States. The company's services include: Interactive Television Solutions, Broadband Internet Solutions, Content Solutions, Professional Solutions and Advertising Media Solutions. LodgeNet Interactive Corporation owns and operates businesses under the industry leading brands: LodgeNet, LodgeNetRX, and The Hotel Networks.

LNET News:

November 10 - LodgeNet, LG Electronics Announce New Free-to-Guest and Video On Demand Solutions Based On 'Pro:Centric' Technology

New Solutions Will Provide One-to-One Guest Services Through In-room Interactive Platform, Reducing the Need for Expensive Set-Top Boxes

LodgeNet Interactive Corporation (Nasdaq: LNET) and LG Electronics are collaborating on the development of an Interactive Electronic Program Guide (IEPG) as the first in what is expected to be a series of in-room interactive applications based on the new Pro:Centric(TM) standards-based applications platform.

Announced at the 2008 International Hotel/Motel & Restaurant Show, LG Electronics' new Pro:Centric technology is designed to support interactive applications such as program guides, games, Web services and other applications designed to communicate with and connect guests to hotel services.

LG has chosen LodgeNet as its lead associate in developing applications and support services for this new platform, and solutions developed for the platform will be compatible with a range of existing LodgeNet free-to-guest (FTG) TV and video-on-demand (VOD) solutions.

"LodgeNet and LG are working together to bring this new platform to the hospitality industry to further enhance the in-room guest experience," said Dave Bankers, LodgeNet Senior Vice President of Product and Technology Development. "Our first collaborative application is an IPG. We are also evaluating additional applications such as hotel information and environmental controls to take advantage of the Pro:Centric platform."

Richard Lewis, senior vice president of Research and Technology for LG Electronics' U.S. R&D subsidiary, said, "We're joining forces with LodgeNet on this initiative based on its unmatched capabilities in delivering innovative new media and connectivity solutions for the hospitality industry. Working with LodgeNet allows LG to quickly introduce compelling applications for the Pro:Centric platform and ensure that hoteliers have the service and support required to operate and extend this environment thereby maximizing the return on their existing entertainment system investment."

Customized Content Delivery

LG Electronics' Pro:Centric LG700H LCD HDTV series, combined with LodgeNet's various TV-based platforms and products, supports a broad range of in-room TV services including standalone FTG to VOD and expanded Web based applications. By working together on these new solutions, LodgeNet and LG will increase the capacity and potential of the guest room television to serve as a robust point of convergence for content and services from various sources to meet the marketing, information and entertainment needs of hoteliers and their guests.

Optimized for LodgeNet TV systems, LG's LG700H HDTV models are not only equipped with the Pro:Centric platform, but also provide hoteliers with the industry-standard Pro:Idiom® digital rights management system, for the secure, broad deployment of HDTV and other high-value digital content throughout the hotel. In addition, this content is delivered in multiple formats including built-in MPEG-2 and MPEG-4 technology that decodes high-definition (HD) content, so hoteliers get more HD channels and can provide guests with expanded entertainment options.

ABOUT LG ELECTRONICS USA, INC.

LG Electronics USA, Inc., based in Englewood Cliffs, N.J., is the North American subsidiary of LG Electronics, Inc., a global force in consumer electronics, home appliances and mobile communications. In the United States, LG Electronics sells a wide range of consumer electronics (digital display and digital media) products, mobile phones and digital appliances under LG's "Life's Good" marketing theme.

ABOUT LG COMMERCIAL PRODUCTS,

LG Commercial Products is a division of LG Electronics USA, serves digital signage, lodging and hospitality, business-to-business (systems integration and industrial), healthcare, and channel markets (education and government). Based in Lincolnshire, Ill., with its dedicated engineering and customer support team, LG Commercial furnishes a broad range of products and services tailored to the particular needs of business environments.

CELL THERAPEUTICS INCORPORATED (NASDAQ: CTIC)
"Up 3.03% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CTIC.php

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, visit www.celltherapeutics.com.

CTIC News:

November 10 - Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher Compared to Standard Chemotherapy

Cell Therapeutics, Inc. (Nasdaq: CTIC) (CTI) announced that it achieved the primary efficacy endpoint of its phase III EXTEND (PIX301) trial of pixantrone (BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) based on a preliminary intent to treat efficacy analysis. Patients randomized to treatment with pixantrone achieved a high rate of confirmed and unconfirmed complete remissions compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02). No patient (0%) in the standard chemotherapy arm achieved a confirmed complete remission compared to 8/70 (11%) of pixantrone recipients. Pixantrone treatment also significantly increased the overall response rate (CR/uCR+PR) with (26/70 (37.1%) for pixantrone arm compared to 10/70 (14.3%) for the control arm, p = 0.003). CR/uCR and ORR were determined by an independent assessment panel that was blinded to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent Data Safety Monitoring Committee and no serious concerns were raised. Seventy-four percent of patients discontinued therapy for disease progression or death, the majority of which were in the standard chemotherapy control arm.

CTI plans to submit complete study data for presentation at a major scientific conference. CTI also intends to request a pre-NDA meeting with the FDA and expects to begin submission of a rolling New Drug Application (NDA) to the FDA in early 2009.

"This positive phase III study is validation of Cell Therapeutics Inc.'s capabilities in acquiring attractive drug candidates, and designing and implementing a successful phase III trial," said James A. Bianco, M.D., CEO of Cell Therapeutics. "These data are consistent with the extensive experience with pixantrone in our phase I and phase II studies and demonstrate the ability to offer patients with advanced, relapsed NHL the potential to obtain a clinically meaningful response like a complete remission, despite having failed multiple other courses of chemotherapy or immuno-chemotherapy."

The EXTEND clinical trial is a phase III single-agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician. The trial was designed to examine the complete remission (CR) or unconfirmed complete remission (uCR) rate, overall survival (OS) and progression-free survival (PFS). The study received Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in 2004 and pixantrone has received fast track designation for this indication.

CTI intends to further evaluate additional details of the study and will provide complete safety and progression-free survival information comparing treatment assignments which is currently being assembled for analysis.

Cell Therapeutics will be presenting at the Rodman & Renshaw Healthcare Conference on November 11, 2008 at 10:45 am Eastern time and a webcast will be available at www.celltherapeutics.com.

ABOUT PIXANTRONE

Pixantrone (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents, was discovered by our scientists in Bresso, Italy. Pixantrone is a novel DNA major groove binder that contains an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

ABOUT NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms — aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute's SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that in the United States 66,120 people are expected to be diagnosed with NHL in 2008. Additionally, approximately 19,160 are expected to die from this disease in 2008.

GENVEC INCORPORATED (NASDAQ: GNVC)
"Up 13.88% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GNVC.php

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product candidate, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer and is being evaluated in additional clinical trials in other tumor types. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including foot-and-mouth disease, malaria, HIV, respiratory syncytial virus (RSV), HSV-2, and influenza.

GNVC News:

November 10 - TNFerade™ Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer

Designation Represents a Significant Regulatory Achievement for TNFerade™

GenVec, Inc. (Nasdaq: GNVC) announced that TNFerade™ has been granted Fast Track product designation by the U.S. Food and Drug Administration (FDA) for its proposed use in the treatment of locally advanced pancreatic cancer. The designation is based on GenVec having “provided evidence of the potential to improve survival in patients with pancreatic cancer.”

Drugs designated for Fast Track are intended for the treatment of a life-threatening condition and have demonstrated the potential to address unmet medical needs. Fast track designation does not apply to a product alone but to a combination of a product and specific indication. This designation provides for expedited regulatory review. Should events warrant, GenVec will be eligible to submit a U.S. biologics license application (BLA) for TNFerade on a rolling basis. Under certain conditions, this permits the FDA to review sections of the BLA prior to receiving the complete submission.

“This Fast Track designation is an important step in the increasing focus on the clinical potential of TNFerade as a treatment for locally advanced pancreatic cancer,” stated Mark Thornton, M.D., Ph.D., Senior Vice President of Product Development at GenVec. “As further data emerge regarding TNFerade, we look forward to working closely with the FDA to potentially expedite the review process for TNFerade.”

ABOUT TNFERADE™

TNFerade is an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNFα), an immune system protein with potent and well-documented anti-cancer effects, for direct injection into tumors. After administration, TNFerade stimulates the production of TNFα in the tumor. GenVec is developing TNFerade for use in combination with radiation and/or chemotherapy for the treatment of various cancers.

XO HOLDINGS INCORPORATED (OTCBB: XOHO)
"Up 33.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/XOHO.php

XO Communications, a subsidiary of XO Holdings, Inc., is a leading nationwide provider of advanced communications services and solutions for businesses, enterprises, government, carriers and service providers. Its customers include more than half of the Fortune 500, in addition to leading cable companies, carriers, content providers and mobile network operators. Utilizing its unique combination of high-capacity nationwide and metro networks and broadband wireless capabilities, XO offers customers a broad range of managed voice, data and IP services with proven performance, scalability and value in more than 75 metropolitan markets across the United States.

XOHO News:

November 11 - Concentric® Managed Server Offers Enterprise-Class Hosted Services on Cloud Computing Platform

New Managed Server Solution Provides Business Continuity, Flexibility, Security, and Lower Total Cost of Ownership to Small and Medium Size Businesses

Concentric announced the launch of its new service, Managed Server, an enterprise-class, fully managed server solution designed to scale with growing businesses. By offering hosted services in the cloud, Concentric provides enterprise-level capabilities such as fault-tolerance, high availability, scalability, and unsurpassed security without the capital expenditures and on-going maintenance for UPS capacity and upgrades, data systems and backup, cooling, power capacity and reliability, network capacity, physical and logical security, and other IT infrastructure. Runaway IT budgets will be a thing of the past for SMBs that move to Managed Server.

"The average small business has a shared server, email server, fax server, networked printer/copier, along with a VOIP phone system. They probably have an IT closet that is overheated, under-maintained, and not backed-up," said Craig Collins, president, Concentric, a business unit of XO Communications. "By getting rid of old, underpowered servers and moving them onto the cloud, SMBs will get better economics, better performance, and higher reliability. Just as your phone system is moving out of the office, your IT should move out of your office."

The Concentric Cloud Computing Platform is a fault-tolerant, high availability, distributed computing infrastructure. Key benefits include on-demand processing power, bandwidth and storage capacity, high availability, fast error recovery, and lower total cost of ownership. Complete maintenance of hardware, operating systems, pre-installed applications, and 24x7 phone-based technical support are included in the base price.

"The beauty of hosting infrastructure in the cloud is that it delivers enterprise-grade technology to SMBs with low up-front costs and easy scalability. Adding a management layer allows SMBs to reap even more benefits," said Phil Shih, Research Analyst, Mass Market Hosting, Tier1 Research. "Tier1 Research continues to see strong growth in mass-market hosting as SMBs continue to look for third party providers to take care of all their IT needs."

Managed Server Features and Benefits

Managed Server offers full administrator control for Windows® and Linux operating systems which are accessed using Remote Desktop and SSH (Secure Shell) respectively, as well as with third party tools, including VPNs for secure connections. Managed Server is ideal for multi-server configurations as well as variable loads where customers may need to upgrade servers (CPUs, memory, disk) dynamically. Other features and benefits include:

* Scalability - Dynamic real-time resource allocation with near zero downtime; add CPU, memory, and storage quickly and easily

* Availability - Fast failover with no single point-of-failure and 99.9 percent SLA on power, network, and server availability

* Reliability - Network and hardware redundancies with daily backups

* Security - Both network and OS-based firewalls, continuous monitoring of network and server activity

* Flexibility - SMBs can install and run their own applications and host their own Internet web sites, intranets, and extranets; SMBs also control all files and processes on the server via administrative-level access

* Manageability - Centralized console for status and management of all servers; flexible management levels based on customer requirements; single-login account management and consolidated invoice; easily add other Concentric Hosted Services

Pricing and Availability

Concentric Managed Server is available immediately. Pricing starts at $195.00 a month.

ABOUT CONCENTRIC

Concentric provides enterprise hosted IT solutions that streamline IT management, improve security and uptime, and reduce costs for organizations of all sizes. The company's innovative technology platform is based on patented, clustered architecture that delivers superior reliability, scalability, and security. Services include applications hosting, business-class email, anti-spam and anti-virus solutions, and managed servers, all backed by 24x7 live customer support and an in-house Professional Services group to help businesses that need additional resources. Concentric is a business unit of XO Communications, a leading national telecommunications provider.

DECODE GENETICS INCORPORATED (NASDAQ: DCGN)
"Up 4.97% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DCGN.php

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma. deCODE is delivering on the promise of the new genetics.

DCGN News:

November 6 - deCODE genetics Announces Third Quarter 2008 Financial Results

deCODE Genetics Inc. (Nasdaq: DCGN) announced its consolidated financial results for the quarter ended September 30, 2008. A conference call to discuss the quarter's results, recent operating highlights and a strategic update will be webcast live tomorrow, Friday, November 7, at 8:00am EST/1pm GMT (details below).

Operating loss for the third quarter 2008 was $11.3 million, compared to $22.2 million for the third quarter 2007. Operating loss for the first nine months of 2008 declined to $44.4 million from $65.7 million for the first nine months of 2007.

Net loss for the quarter ending September 30, 2008 was $17.9 million, compared to $24.2 million for the third quarter 2007. Net loss for the first nine months of 2008 was $62.9 million, compared to $63.1 million for the first nine months of last year. In addition to operating loss, net loss figures for the periods presented include interest expense and, in the 2008 periods, unrealized loss resulting from the revaluation of the company's auction rate securities investments. The nine-month figure for 2007 also includes a one-time payment deCODE received related to the settlement of an intellectual property suit.

Basic and diluted net loss per share was $0.29 for the third quarter 2008, compared to $0.40 for the same quarter in 2007. For the first nine months of 2008, basic and diluted net loss per share was $1.03, unchanged from that for the first nine months of last year. At the close of the third quarter 2008, the company had approximately 61.8 million shares outstanding.

Revenue for the third quarter this year was $12.0 million, compared to $10.9 million for the same period a year ago. For the first nine months of 2008, revenue was $42.0 million, compared to $27.1 million for the same period last year. As of September 30, 2008, the company had $17.7 million in deferred revenue that will be recognized over future reporting periods. The period-on-period increase in revenue for the third quarter and first nine months of 2008 was driven principally by growth in the company's genomic services business, which includes the company's diagnostics, deCODEme(TM) personal genome analysis, and contract genotyping businesses.

Research and development expense was $5.7 million for the third quarter of this year, compared to $14.1 million for the same period last year. For the first nine months of 2008, R&D expense was $26.3 million, compared to $41.3 million for the first nine months of 2007. Our research and development expense in the first nine months of this year reflects the conclusion of clinical pharmacology studies in our most advanced drug development programs, preparations for the IND filing for our PDE4 modulator DG071, the launch of our prostate cancer, glaucoma and breast cancer tests, and the advancement of gene and target discovery work in a range of major disease areas.

Selling, general and administrative expense for the third quarter of 2008 was $6.7 million, compared to $7.1 million for the 2007 period. For the first nine months of the year, SG&A expense was $21.0 million in 2008 and $19.4 million in 2007.

At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at June 30, 2008 and $64.2 million at December 31, 2007. The net utilization of liquid funds in the three and nine-month periods ended September 30, 2008 was $12.0 million and $52.4 million, respectively. At September 30, 2008, the company had $35.5 million in cash, cash equivalents and investments, comprised of the $11.8 million in cash and cash equivalents, as well as $5.5 million in restricted investments in U.S. Treasury Bills and $18.2 million in illiquid, non-current investments in auction rate securities. At December 31, 2007, the company had $94.1 million in cash, cash equivalents, restricted cash equivalents, and investments.

The company is undertaking a review of its long-term business strategy with the goal of sharpening the focus of its business, selling assets, securing partnerships, and utilizing the resources generated to support product development and marketing efforts in its core business. The company has utilized a 30-day grace period for the scheduled October 15 interest payment on its 3.5% Senior Convertible Notes due 2011 and is reviewing methods for making this payment. Given its current liquid assets, and without paying the interest on its Notes from its present funds, the company must obtain further financial resources through either the implementation of strategic alternatives, corporate partnerships, or the sale of or loans secured by its auction rate securities in order to continue operations beyond the end of this year. The company is focused on reducing expenses and speeding the evaluation of its strategic options in order to obtain the resources to do so.

deCODE has significant operations in Iceland and pays a large proportion of its fixed costs in Icelandic krona, while its sales are generally denominated in US dollars and its reporting currency is the US dollar. During the third quarter and beginning of the fourth quarter the global financial crisis caused significant economic turmoil in Iceland. As a result, the value of the Icelandic krona has declined significantly versus the US dollar. The turmoil in the Icelandic financial sector and economy as a whole have not to date had any significant adverse impact on deCODE or its day to day operations. deCODE is monitoring closely the situation in Iceland, the principal impact of which for the company has been to decrease the dollar value of our krona-denominated costs. deCODE's most significant operating expenses denominated in krona include salaries and rental payments on our leased facilities and capital equipment. In as far as the krona decreases in value versus the U.S. dollar that portion of our overall operating expenses that are payable in krona will decrease.

"Over the past few months we have continued to bring forward new products for treating and preventing common diseases. Utilizing the expertise of our protein crystallography and medicinal chemistry units we have filed an IND on an exciting new PDE4 modulator for Alzheimer's disease that has the potential to avoid some of the side effects of earlier compounds. We have also just launched the first DNA-based test for risk of the common forms of breast cancer, a test which promises to improve the way in which we target intensive screening and thus to catch more cancers earlier. At the same, in a global economic climate in which there is limited access to capital for companies of our size, we believe that the best way to develop and capture the value of our capabilities and product portfolio is to sharpen the focus of our business. We are therefore in the process of reviewing our long-term strategy and will be sharing with you the results of this process in the weeks ahead," said Kari Stefansson, CEO of deCODE.

SUNESIS PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)
"Up 12.63% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, visit www.sunesis.com.

SNSS News:

November 6 - Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

Voreloxin Demonstrates Promising Clinical Activity in Patients with Difficult-to-Treat Cancers

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented from Phase 1 and Phase 1b/2 studies in patients with acute myeloid leukemia (AML) showed that preliminary clinical responses were observed in the relapsed/refractory AML population and the data supports further clinical development for voreloxin both as a single agent and in combination with cytarabine. Preliminary efficacy results previously presented from an ongoing Phase 2 trial demonstrate single agent activity of voreloxin in advanced platinum-resistant ovarian cancer and that the drug is generally well tolerated in this difficult-to-treat patient population.

"We believe that voreloxin has the potential to change the standard of care in AML and platinum-resistant ovarian cancer and look forward to reporting updated results of our AML trials at ASH," said Daniel Swisher, Chief Executive Officer, Sunesis Pharmaceuticals. "Our goal is to advance voreloxin into a pivotal trial in AML by the end of 2009."

Phase 1 and 1b/2 Studies of Voreloxin in AML

Data presented from a completed Phase 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that single agent voreloxin was generally well tolerated, with the most frequently observed dose limited toxicity (DLT) being reversible grade 3/4 oral mucositis. The researchers concluded that single agent activity in the relapsed/refractory AML population supports further clinical development.

Researchers also presented initial data from an ongoing Phase 1b/2 study testing voreloxin in combination with cytarabine. The Phase 1b/2 trial is designed to evaluate safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with a fixed dose of 400 mg/m2/day of cytarabine given as a continuous infusion for five days.

Of 11 evaluable patients in the first three cohorts, 3 patients have achieved a complete remission (one at 20 mg/m2 of voreloxin and two at 34 mg/m2 of voreloxin). Six patients were enrolled in cohort 4 (50 mg/m2 of voreloxin) and one had complete remission and one had a complete remission without full platelet recovery.

A copy of this presentation entitled "Voreloxin (SNS-595): An Active Agent in AML" is available at http://www.sunesis.com.

A Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

In this ongoing Phase 2 study, 65 women with advanced platinum-resistant ovarian cancer were administered voreloxin at a dose of 48 mg/m2 as a single agent once every three weeks. At this dose, two patients have had a complete response, five have had partial responses and 23 achieved stable disease for 90 days or more. This equates to an overall disease control rate of 46%. Thirty-five women in the Phase 2 study were given 60 mg/m2 once every four weeks. Of the 32 patients evaluable for efficacy at this dose, one patient has had a complete response, two have had partial responses and 20 achieved stable disease thus far.

Voreloxin was also generally well tolerated in platinum-resistant ovarian cancer patients. Grade 3/4 non-hematologic adverse events (greater than or equal to 5%) at the 48 mg/m2 dose were low: fatigue (14%), vomiting (6%) and infections (8%). Low rates of febrile neutropenia occurred in 8% of the 65 patients evaluable for safety at 48 mg/m2 dosed every three weeks and 6% of the 35 patients evaluable for safety at 60 mg/m2 dosed every four weeks. Based on this emerging safety profile and low incidence of febrile neutropenia, the dose of voreloxin has been escalated to 75 mg/m2 dosed every four weeks. Sunesis expects to complete enrollment of the 75 mg/m2 cohort by the end of 2008.

A copy of this presentation entitled "Voreloxin (SNS-595) in Platinum-Resistant Ovarian Cancer" is available at www.sunesis.com.

ABOUT VORELOXIN

Voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site- selective DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

ABOUT ACUTE MYELOID LEUKEMIA

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

ABOUT OVARIAN CANCER

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.